Striking a Balance: Innovation, Equity, and Consistency in AI Health Technologies.

Eric Perakslis^1,2, Kimberly Nolen³, Ethan Fricklas¹, Tracy Tubb¹

¹Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, United States.

²Pluto Health, Durham, NC, United States.

³Pfizer Inc, New York, NY, United States.

PubMed PMC DOI PDF

Abstract

With the explosion of innovation driven by generative and traditional artificial intelligence (AI), comes the necessity to understand and regulate products that often defy current regulatory classification. Tradition, and lack of regulatory expediency, imposes the notion of force-fitting novel innovations into pre-existing product classifications or into the essentially unregulated domains of well…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.